Andreessen Marc L's Form 4 filing
Scribe Therapeutics, Inc. (SCTX) · filed Jul 29, 2026
- Accession no.
- 0001231919-26-000813
- Filed
- Jul 29, 2026, 7:09 PM ET
- Trade date
- Jul 27, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market purchases total $5.00M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Andreessen Marc LCIK 0001160077 | 10% Owner |
| Horowitz Benjamin ACIK 0001166586 | 10% Owner |
| AH Bio Fund II, L.P.CIK 0001725721 | 10% Owner |
| AH Equity Partners Bio II, L.L.C.CIK 0001725722 | 10% Owner |
| AH Bio Fund III, L.P.CIK 0001799477 | 10% Owner |
| AH Equity Partners Bio III, L.L.C.CIK 0001799478 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 27, 2026 | Common Stock | CConversionAcquired | +2,051,742 | –F1 | – | 2,051,742 | Indirect | |
| Jul 27, 2026 | Common Stock | CConversionAcquired | +697,650 | –F1 | – | 697,650 | Indirect | |
| Jul 27, 2026 | Common Stock | PPurchaseAcquired | +333,333 | $15.00 | +$4,999,995 | 2,385,075 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 27, 2026 | Common Stock | CConversionDisposed | −2,051,742 | $0.00 | $0 | 0 | Indirect | |
| Jul 27, 2026 | Common Stock | CConversionDisposed | −697,650 | $0.00 | $0 | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Series A Preferred Stock and Series B Preferred Stock converted into Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration, on a 5.9218-for-one basis, and had no expiration date.
Referenced by the price of 2 transactions in Table I.